Agenus dives deeper into checkpoint inhibitors

Agenus is adding to its capabilities in checkpoint inhibitors with the licensing of antibody programs from Italy's Diatheva.

The Massachusetts biotech announced 20 July that it has gotten the worldwide development and commercialization rights to Diatheva's CEACAM1 (carcinoembryonic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category